Keytruda 50mg

In the ever-evolving landscape of cancer therapeutics, a revolutionary approach has emerged, harnessing the body’s own immune system to combat this formidable disease. Keytruda 50mg, also known by its generic name pembrolizumab, stands as a pioneering immunotherapy agent, offering hope and improved outcomes to patients battling various forms of cancer.

Dosage form

, , ,

Pack size


50mg in 2mL



Generic Name (Ingredient)


Assuming your emergency circumstances for this product, visit Urgent Quotation page. Besides, for any pharmaceutical questions, please ask us in the comments section.


Keytruda 50mg Mechanism

Keytruda is a humanized monoclonal antibody that targets the programmed death receptor-1 (PD-1) pathway, a critical regulator of the immune system’s ability to recognize and eliminate cancer cells. By binding to and blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, Keytruda unleashes the full potential of the body’s T-cells, enabling them to mount a more effective anti-tumor response.

This innovative mechanism of action represents a paradigm shift in cancer treatment, as it harnesses the body’s natural defenses rather than relying solely on traditional chemotherapeutic agents or targeted therapies. By removing the brakes on the immune system, Keytruda 50mg empowers the body to fight back against the malignant cells that have evaded its surveillance.

A Versatile Weapon Against Cancer

Keytruda’s versatility is evident in its wide range of approved indications, spanning various types of cancer in both adult and certain pediatric populations. These include melanoma, non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and several other solid tumors and hematological malignancies.

In the realm of melanoma, Keytruda has proven to be a game-changer, offering improved survival rates and prolonged remissions for patients with advanced or metastatic disease. Similarly, in non-small cell lung cancer, Keytruda 50mg has demonstrated remarkable efficacy, both as a monotherapy and in combination with other treatments, providing a new standard of care for this challenging malignancy.

Beyond these indications, Keytruda’s applications continue to expand, offering hope to patients with advanced or metastatic cancers of the kidney, bladder, urinary tract, colorectal, liver, breast, cervix, and uterus, among others. Its ability to target tumors with specific molecular characteristics, such as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status, further broadens its therapeutic potential.

Dosage and Administration

Keytruda is administered as an intravenous infusion, with the dosage and frequency tailored to the specific type of cancer being treated. For instance, in the treatment of unresectable or metastatic melanoma, the recommended dosage is 200 mg every 3 weeks or 400 mg every 6 weeks, until disease progression or unacceptable toxicity occurs.

In certain cases, Keytruda 50mg may be used in combination with other therapies, such as chemotherapy or targeted agents, further enhancing its efficacy. These combination regimens have shown promising results in various cancer types, including metastatic non-small cell lung cancer, where Keytruda is used in conjunction with pemetrexed and platinum chemotherapy for nonsquamous tumors, or carboplatin and paclitaxel/nab-paclitaxel for squamous cell carcinomas.

Keytruda 50mg
Keytruda 50mg

Patient Selection and Biomarker-Guided Therapy

The selection of patients for Keytruda treatment is guided by the presence of specific biomarkers, such as the expression of PD-L1 or the presence of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in tumor specimens. These biomarkers help identify patients who are more likely to respond favorably to Keytruda, optimizing treatment outcomes and ensuring that the right patients receive the right therapy.

Ongoing research efforts are focused on identifying additional biomarkers and refining patient selection criteria, further enhancing the precision and personalization of Keytruda’s use in cancer treatment.

Dosage Modifications and Precautions

As with any potent therapy, Keytruda 50mg requires careful monitoring and potential dosage modifications in the event of adverse reactions. Healthcare providers should consult the full prescribing information for specific instructions on dosage adjustments and precautions, including contraindications, warnings, and potential drug interactions.

While Keytruda 50mg is generally well-tolerated, patients may experience mild to moderate side effects, such as fatigue, rash, diarrhea, fever, cough, decreased appetite, and itching. However, more serious side effects, known as immune-related adverse events (irAEs), can occur, affecting various organ systems, including the lungs, liver, kidneys, and endocrine glands.

Prompt recognition and management of these side effects are crucial to ensure patient safety and maintain the efficacy of the treatment. Close monitoring and open communication between patients and their healthcare team are essential in mitigating potential risks and optimizing outcomes.

Pregnancy and Lactation

Due to the potential risks associated with Keytruda’s mechanism of action, its use during pregnancy should be carefully evaluated, weighing the potential benefits against the risks to the fetus. Animal studies have suggested that blocking the PD-1/PD-L1 pathway may disrupt maternal immune tolerance and increase the risk of fetal loss.

Additionally, caution is advised when considering breastfeeding while receiving Keytruda 50mg, as the drug’s presence in breast milk and its effects on the breastfed child are not fully understood. Healthcare providers should provide guidance and support to patients navigating these delicate situations, ensuring that informed decisions are made based on the latest available evidence.

Comprehensive Care and Monitoring

Effective cancer treatment with Keytruda requires a multidisciplinary approach, involving close collaboration between oncologists, nurses, pharmacists, and other healthcare professionals. Regular monitoring of treatment response, side effects, and overall patient well-being is essential to ensure optimal outcomes and quality of life.

Supportive care measures, such as symptom management, nutritional support, and psychosocial counseling, play a crucial role in enhancing the patient’s experience and improving their overall well-being throughout the treatment journey.

Aspect Details
Side Effects Common: Fatigue, rash, diarrhea, fever, cough, decreased appetite, itching, shortness of breath, constipation, bone/joint pain, abdominal pain, nausea, low thyroid hormone levels.

Serious (immune-related adverse events): Lung problems (cough, shortness of breath, chest pain), intestinal problems (diarrhea, severe abdominal pain), liver problems (jaundice, nausea/vomiting, dark urine, easy bruising/bleeding), kidney problems (decreased urine output, blood in urine, swelling, loss of appetite), skin problems (rash, itching, blistering/peeling), hormone gland problems (headaches, eye sensitivity, rapid heartbeat, sweating, fatigue, weight changes, increased hunger/thirst, hair loss, voice changes, mood/behavior changes).

Dosage Varies based on cancer type and treatment regimen. Examples:
– Melanoma: 200 mg IV every 3 weeks or 400 mg every 6 weeks
– Non-Small Cell Lung Cancer: 200 mg IV every 3 weeks or 400 mg every 6 weeks
– Combination therapy for metastatic NSCLC: With pemetrexed and platinum chemotherapy (nonsquamous) or carboplatin and paclitaxel/nab-paclitaxel (squamous)
Benefits Activates the immune system to recognize and attack cancer cells, offering improved outcomes and survival rates in various types of cancer, including melanoma, lung cancer, head and neck cancer, and others. Provides a new standard of care for challenging malignancies.
Usage Intravenous infusion, typically administered in a healthcare setting under the supervision of a healthcare professional.
Contraindications No specific contraindications, but caution advised in patients with autoimmune diseases, pneumonia, or lung inflammation.
Pregnancy and Lactation Should not be used during pregnancy unless clearly needed, as it may increase the risk of fetal harm. Breastfeeding is not recommended during treatment and for 4 months after the last dose.

In the ever-evolving battle against cancer, Keytruda 50mg stands as a beacon of hope, representing the cutting edge of immunotherapy and offering patients a chance at improved outcomes and a better quality of life. With its remarkable efficacy and ongoing research efforts, this groundbreaking therapy continues to push the boundaries of what is possible in cancer treatment, ushering in a new era of personalized and targeted approaches.


There are no reviews yet.

Be the first to review “Keytruda 50mg”

Your email address will not be published. Required fields are marked *

Use the form below to report an error

Please answer the questions as thoroughly and accurately as possible. Your answers will help us better understand what kind of mistakes happen, why and where they happen, and in the end the purpose is to build a better archive to guide researchers and professionals around the world.

If an image of the drug is not available on the Wikikenko health encyclopedia, you have the option to submit images/leaflets of the product. Following verification by our pharmaceutical specialist, your submitted images/leaflets will be included in our archive, with due acknowledgment of your contribution. Your cooperation in this matter would greatly assist researchers in finding the information they seek. Upload Images/Leaflet (Less than 2MB)

No Choosen File
(Max 2 MB)

The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. always seek the advice for your physician or another qualified health provider with any questions you may have regarding a medical condition. Always remember to

  1. Ask your own doctor for medical advice.
  2. Names, brands, and dosage may differ between countries.
  3. When not feeling well, or experiencing side effects always contact your own doctor.


The truth is that when we’re sick, or worried about getting sick, the internet won’t help.

According to Wikipedia, cyberchondria is a mental disorder consisting in the desire to independently make a diagnosis based on the symptoms of diseases described on Internet sites.

Why you can't look for symptoms on the Internet

If diagnoses could be made simply from a textbook or an article on a website, we would all be doctors and treat ourselves. Nothing can replace the experience and knowledge of specially trained people. As in any field, in medicine there are unscrupulous specialists, differences of opinion, inaccurate diagnoses and incorrect test results.


People also search for…

More results…

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

The expert search feature is especially useful for healthcare professionals, researchers, and scientists who require accurate and up-to-date information on pharmaceutical products. By narrowing down their searches using filters, they can easily access the relevant data they need, making informed decisions about treatment options or drug research endeavors.

Expert Search  →

Recent comments